Metraipolis › archive › dc_999430366a2f

Caregivers of children with HIV in Botswana prefer monthly IV Broadly Neutralizing Antibodies (bNAbs) to daily oral ART — Europe PMC PMID:38536810

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/38536810
DOI
10.1371/journal.pone.0299942
License (as archived)
CC0-1.0
Archived
2026-10-06T20:06:13.253Z
SHA-256 of the archived text
b1db76665479ec1f5d79ffdd878f5926a2d7a810cec018f4ad507914f6b0181d
Stable URL of this page
https://metraipolis.com/documento/dc_999430366a2f

How to cite

Caregivers of children with HIV in Botswana prefer monthly IV Broadly Neutralizing Antibodies (bNAbs) to daily oral ART — Europe PMC PMID:38536810 — Europe PMC (en), https://europepmc.org/article/MED/38536810 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_999430366a2f (Metraipolis archive dc_999430366a2f, sha256 b1db76665479ec1f5d79ffdd878f5926a2d7a810cec018f4ad507914f6b0181d)
BibTeX
@misc{dc999430366a2f,
  title = {Caregivers of children with HIV in Botswana prefer monthly IV Broadly Neutralizing Antibodies (bNAbs) to daily oral ART — Europe PMC PMID:38536810},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/38536810},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_999430366a2f; sha256 b1db76665479ec1f5d79ffdd878f5926a2d7a810cec018f4ad507914f6b0181d},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/38536810. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Introduction: Monthly intravenous infusion of broadly neutralizing monoclonal antibodies may be an attractive alternative to daily oral antiretroviral treatment for children living with HIV. However, acceptability among caregivers remains unknown. Methods: We evaluated monthly infusion of dual bNAbs (VRCO1LS and 10-1074) as a treatment alternative to ART among children participating in the Tatelo Study in Botswana. Eligible children aged 2-5 years received 8-32 weeks of bNAbs overlapping with ART, and up to 24 weeks of bNAbs alone as monthly intravenous infusion. Using closed-ended questionnaires, we evaluated caregiver acceptability of each treatment strategy prior to the first bNAb administration visit (pre-intervention) and after the completion of the final bNAb administration visit (post-intervention). Results: Twenty-five children completed the intervention phase of the study, and acceptability data were available from 24 caregivers at both time points. Responses were provided by the child's mother at both visits (60%), an extended family member at both visits (28%), or a combination of mother and an extended family member (12%). Caregiver acceptance of monthly bNAb infusions was extremely high both pre-and post-intervention, with 21/24 (87.5%) preferring bNAbs to ART pre-intervention, and 21/25 (84%) preferring bNAbs post-intervention. While no caregiver preferred ART pre-intervention, 2/25 preferred it post-intervention. Pre-intervention, 3 (13%) caregivers had no preference between monthly bNAbs or daily ART, and 2 (8%) had no preference post-intervention. Pre-intervention, the most common reasons for preferring bNAbs over ART were the perception that bNAbs were better at suppressing the virus than ART (n = 10) and the fact that infusions were dosed once monthly compared to daily ART (n = 9). Post-intervention, no dominant reason for preferring bNAbs over ART emerged from caregivers. Conclusions: Monthly intravenous bNAb infusions were highly acceptable to caregivers of children with HIV in Botswana and preferred over standard ART by the majority of caregivers. Clinical trial number: NCT03707977.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2024 (prima pubblicazione 2024-03-27).
Identificativi: PMID 38536810 · PMCID PMC10971757 · DOI 10.1371/journal.pone.0299942.
Descrittori MeSH principali: HIV-1; HIV Infections.
Pagina: https://europepmc.org/article/MED/38536810 — https://doi.org/10.1371/journal.pone.0299942. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-06T18:30:56.414Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.